阿替普酶注射剂联合瑞舒伐他汀钙片治疗急性脑梗死患者的临床研究  

Clinical trial of alteplase injection combined with rosuvastatin calcium tablets in the treatment of acute cerebral infarction

作　　者：楼赵彦[1,2] 宋水江 LOU Zhao-yan;SONG Shui-jiang(Department of Internal Medicine-Neurology,The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,Zhejiang Province,China;Department of Internal Medicine Neurology,Zhuji People’s Hospital,Zhuji 311800,Zhejiang Province,China)

机构地区：[1]浙江大学医学院附属第二医院神经内科,浙江杭州310009 [2]诸暨市人民医院神经内科,浙江诸暨311800

出　　处：《中国临床药理学杂志》2020年第11期1413-1415,共3页The Chinese Journal of Clinical Pharmacology

基　　金：浙江省医药卫生科技课题资助项目(2017KY06);浙江省卫生适宜技术成果转化计划(A类)课题资助项目(2016ZHA002)。

摘　　要：目的观察阿替普酶注射剂联合瑞舒伐他汀钙片治疗急性脑梗死患者的临床疗效及安全性。方法将102例急性脑梗死患者随机分为对照组和试验组,每组51例。对照组给予瑞舒伐他汀片每次10 mg,qd,口服;试验组在对照组治疗的基础上,给予阿替普酶每天0.9 mg·kg^-1,先于1 min内静脉推注10%,剩余量在1 h内泵入。2组患者均连续治疗2周。比较2组患者的临床疗效,神经功能缺损评分(NIHSS),以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为96.08%(49例/51例)和80.39%(41例/51例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的NIHSS分别为(7.28±1.46)和(11.37±2.84)分,差异有统计学意义(P<0.05)。2组患者的药物不良反应均以消化道出血、牙龈出血和泌尿系统出血为主。试验组和对照组的总药物不良反应发生率分别为9.80%和27.45%,差异有统计学意义(P<0.05)。结论阿替普酶注射剂联合瑞舒伐他汀钙片治疗急性脑梗死患者的临床疗效确切,其能有利于神经功能修复,且安全性较高。Objective To observe the clinical efficacy and safety of alteplase injection combined with rosuvastatin calcium tablets in the treatment of acute cerebral infarction.Methods A total of 102 patients with acute cerebral infarction were randomly divided into control group and treatment group with 51 cases per group.Control group was given rosuvastatin tablets 10 mg per time,qd,orally.Treatment group received alteplase 0.9 mg·kg^-1·d^-1,10%of the dose was injected intravenously within 1 min,and the rest was pumped within 1 hour,on the basis of control group.Two groups were treated for 2 weeks.The clinical efficacy,national institutes of health stroke scale(NIHSS)and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 96.08%(49 cases/51 cases)and 80.39%(41 cases/51 cases)with significant difference(P<0.05).After treatment,the NIHSS scores of treatment and control groups were(7.28±1.46)and(11.37±2.84)with significant difference(P<0.05).The adverse drug reactions of two groups were gastrointestinal bleeding,gingival bleeding and urinary system bleeding.The incidences of total adverse drug reactions in treatment and control groups were 9.80%and 27.45%with significant difference(P<0.05).Conclusion Alteplase injection combined with rosuvastatin calcium tablets has a definitive clinical efficacy and safety in the treatment of patients with acute cerebral infarction,which is beneficial to the repair of neural function.

关 键 词：阿替普酶注射剂 瑞舒伐他汀钙片 急性脑梗死 安全性评价 

分 类 号：R972[医药卫生—药品]